Novo To Follow Lilly And Sell Obesity Shot Wegovy In Vials

Novo Nordisk plans to sell its obesity treatment, Wegovy, in vials, following a similar move by Eli Lilly. While specific pricing details for the vials remain undisclosed, Novo has been actively lowering prices for its obesity medications to enhance its market competitiveness. This strategic shift comes as the demand for weight-loss treatments continues to rise amid growing health concerns related to obesity. By offering Wegovy in vials, Novo aims to provide healthcare professionals greater flexibility in prescribing the drug, potentially reaching a wider patient base. The obesity treatment market is becoming increasingly competitive, with major pharmaceutical companies like Novo and Lilly vying for a larger share. As healthcare providers look for effective solutions for obesity management, such innovations could play a crucial role in addressing this public health challenge in India and beyond.